Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Show more
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.84 | 1.90822353476 | 44.02 | 46.6 | 42.58 | 1744202 | 44.80206363 | CS |
4 | 1.23 | 2.81916112766 | 43.63 | 46.6 | 40.8 | 975699 | 43.66524566 | CS |
12 | 7.17 | 19.0236136906 | 37.69 | 48.61 | 36.5 | 1351729 | 44.36337674 | CS |
26 | 13.87 | 44.7563730236 | 30.99 | 48.61 | 29.55 | 1292598 | 40.60771282 | CS |
52 | 15.11 | 50.7899159664 | 29.75 | 48.61 | 15.4401 | 1666059 | 31.79627586 | CS |
156 | 13.85 | 44.6630119316 | 31.01 | 48.61 | 14.08 | 1144961 | 27.87288112 | CS |
260 | 15.51 | 52.8449744463 | 29.35 | 56.18 | 14.08 | 911429 | 29.12564755 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.